Pharmacogenetics research group
Our research aims at understanding the basis for differences between individuals in human drug metabolism, toxicity and drug response. The emphasis is on genetic polymorphism of the genes encoding drug transporters, drug metabolizing enzymes and drug targets.
Research in our laboratory
The research performed in our laboratory examines the genetic basis for interindividual differences in drug response and adverse drug reactions (ADRs).
We start with patient outliers and examine mechanisms and genetic factors explaining the differences. Genetic biomarkers are identified and used in the clinics.
Among our previous discoveries is the stable gene duplication/amplification in the human genome, the identification of ultrarapid metabolizers of drugs and the identification of several different gene variants of importance for the efficacy of drug treatment.
In addition, we are characterizing the human hepatic epigenome responsible for interindividual differences in drug metabolism and transport, developing a new approach for treatment of colon cancer and utilizing novel mouse models and human genomics in order to elucidate new bases for treatment of depression.
We are also developing novel in vitro methods based on hollow fiber bioreactors and spheroids that can predict drug toxicity, thus finding new ways of producing hepatocytes and non parenchymal liver cells from stem cells in collaboration with Cellectis (Cellartis).
Research funding bodies
- Swedish Research Council
- Swedish Cancer Society
- Hjärnfonden
- European Union, FP7
- Colipa
- Department of Physiology and Pharmacology at KI
- IMI-JU
- AstraZeneca
- Varia
Contact us
Magnus Ingelman-Sundberg
Professor, PhD., group leader, Vice Head of Dept.- Phone:
- +46 8 524 877 35
- Fax:
- +46 8 33 73 27
- E-mail:
- Address:
-
-
Department of Physiology and Pharmacology
Karolinska Institutet
SE-171 77 Stockholm
Sweden
Visiting address: Nanna Svartz väg 2
-
Department of Physiology and Pharmacology
